Benralizumab for <i>PDGFRA</i> -Negative Hypereosinophilic Syndrome

Abstract

In this small phase 2 trial, patients with <i>PDGFRA</i>-negative hypereosinophilic syndrome who received benralizumab for 12 weeks had lower absolute eosinophil counts than those who received placebo. During the open-label phase, clinical and hematologic responses were sustained for 48 weeks in 74% of the patients. Adverse events did not limit treatment. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov numbers, NCT00001406 and NCT02130882.).